While maintaining the lengths of the linker and functional subunits, structural analogues based on a Glu–urea–Glu binding entity showed an 8-fold improvement in the tumour-to-kidney ratio in mice bearing PSMA(+) tumours 21 h p.i. [81]. This evidence concerns the gene FOLH1 and neoplasm.